Please assess the completion status of the following clinical trial:

Trial Title: Open-Label Extension Study Of Rosiglitazone XR As Adjunctive Therapy In Subjects With Mild-to-Moderate Alzheimers

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~* Successful completion of AVA102670 or AVA102672 without safety or tolerability issues. Regular caregiver.~Exclusion criteria:~* Congestive Heart Failure (NYHA 1-4), clinically significant peripheral edema, other neurological conditions that might disqualify participation. SAE, clinically significant laboratory abnormality or significant cardiovascular event during prior study.

- Gender: ALL
- Minimum Age: 51 Years
- Maximum Age: 91 Years
- Healthy Volunteers: f

Study Arms:
- Rosiglitazone XR (Type: EXPERIMENTAL): Investigational drug

Based on this trial design, predict the completion outcome and termination type (if applicable).